Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.52 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CDK9 | P50750 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.30 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909679 | 0.87 | NR1I2 (0.51) | NR1I2CYP2E1PTK2CCNT1CCNA2 | |
| SCHEMBL12909869 | 0.87 | NR1I2 (0.51) | NR1I2CYP2E1PTK2CCNT1CCNA2 | |
| SCHEMBL937892 | 0.81 | NR1I2 (0.43) | NR1I2CYP2E1 | |
| SCHEMBL134450 | 0.80 | NR1I2 (0.71) | NR1I2CYP2E1 | |
| SCHEMBL102077 | 0.80 | NR1I2 (0.71) | NR1I2CYP2E1 | |
| Hydrochloric Acid SCHEMBL141843 | 0.80 | NR1I2 (0.70) | NR1I2CYP2E1 | |
| Hydrochloric Acid SCHEMBL141842 | 0.80 | NR1I2 (0.70) | NR1I2CYP2E1 | |
| SCHEMBL12519283 | 0.77 | NR1I2 (0.61) | NR1I2CYP2E1 | |
| SCHEMBL10207384 | 0.77 | NR1I2 (0.69) | NR1I2CYP2E1 | |
| SCHEMBL15498324 | 0.77 | NR1I2 (0.69) | NR1I2CYP2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885PTK2 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.